# Benefit and Tolerability of IQP-LU-104 in Weight Loss

> **NCT03888911** · NA · COMPLETED · sponsor: **InQpharm Group** · enrollment: 108 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DIETARY_SUPPLEMENT:** High dose IQP-LU-104 (5120mg)
- **DIETARY_SUPPLEMENT:** Low dose IQP-LU-104 (2560mg)
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03888911
- **Lead sponsor:** InQpharm Group
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888911, "Benefit and Tolerability of IQP-LU-104 in Weight Loss". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03888911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*